Close Menu
Daily Guardian EuropeDaily Guardian Europe
  • Home
  • Europe
  • World
  • Politics
  • Business
  • Lifestyle
  • Sports
  • Travel
  • Environment
  • Culture
  • Press Release
  • Trending
What's On

Global left rallies in Paris to make ‘not so radical’ case for taxing billionaires – POLITICO

November 22, 2026

l’accord capote sur fond de désaccord sur les énergies fossiles – POLITICO

November 22, 2026

Climate deal collapses amid fossil fuel rows – POLITICO

November 22, 2026

Emergency workers recover at least six body bags after Indonesian factory fire

November 22, 2026

Theresa May tells Burnham to move on – POLITICO

November 22, 2026
Facebook X (Twitter) Instagram
Web Stories
Facebook X (Twitter) Instagram
Daily Guardian Europe
Newsletter
  • Home
  • Europe
  • World
  • Politics
  • Business
  • Lifestyle
  • Sports
  • Travel
  • Environment
  • Culture
  • Press Release
  • Trending
Daily Guardian EuropeDaily Guardian Europe
Home»Business
Business

AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan

By staffOctober 30, 20263 Mins Read
AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan
Share
Facebook Twitter LinkedIn Pinterest Email

Published on
30 October 2026 – 13:17 GMT+1

AstraZeneca, Britain’s biggest pharmaceutical company, said on Friday that its profit after tax rose 23% to $3.12 billion (€2.79bn) for the July to September period, driven largely by its cancer treatments.

That marks a sharp pick-up from the rise of just over 2% in the previous quarter. The firm also launched a plan to generate $1.5 billion (€1.34bn) in annual savings, which it intends to reinvest mainly in the drugs it has in development.

Revenue grew 7% to $16.2 billion (€14.5bn).

Oncology, its biggest business, accounted for 48% of the total, with sales up 17% to $7.8 billion (€6.99bn), led by lung cancer drug Tagrisso and immunotherapy Imfinzi. Core earnings per share, which exclude items such as restructuring costs and the amortisation of acquired drugs, rose 17% to $2.79.

The savings drive, called Reshaping for Sustainable Growth, will cost up to $2 billion (€1.79bn) in one-off restructuring charges and is due to be largely complete by the end of 2029.

AstraZeneca said the savings would be reinvested in the company, principally in its pipeline of new drugs, as it plans to “redeploy resources” across its existing business to back more than 180 projects in development.

Such restructuring could mean job cuts, though none have been announced.

“With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition,” CEO Pascal Soriot said in a statement.

Generics and China weigh

The growth came despite pressure on older medicines.

Sales of Farxiga, its treatment for diabetes, heart and kidney disease, fell 25% to $1.6 billion (€1.43bn) after cheaper generic versions hit the US market, while blood thinner Brilinta also lost patent protection.

AstraZeneca is also facing volume-based procurement in China, a state bulk-buying scheme that forces drugmakers to cut prices in exchange for large orders.

The company confirmed its outlook for 2026, expecting revenue to grow by a mid-to-high single-digit percentage and core earnings per share by a low double-digit percentage, excluding currency swings.

It remains on track for its target of $80 billion (€71.7bn) in annual revenue by 2030, compared with almost $59 billion (€52.9bn) in 2025, and expects half of that to come from the US.

The company has been leaning further into the American market, adding a direct share listing in New York in February, while also pledging to invest $15 billion (€13.4bn) in China by 2030.

It has reported 12 positive results from late-stage trials so far this year, and is also developing a weight-loss treatment to compete with drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

AstraZeneca shares were up over 4.5% in early trading on Friday.

Additional sources • AFP

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Portugal national public sector strike over pay disrupts key services

Anthropic shares open 34% above IPO price in Nasdaq debut after record listing

Commerzbank welcomes UniCredit commitments after Berlin agreement

Portuguese families spend 83% of net income on rent, Idealista study finds

UK inflation hits 12-month high: What’s driving the rise in prices?

From car parts to drones: German suppliers pivot to defence as auto crisis deepens

Anthropic’s record IPO lands as Nvidia suffers its worst run since 2008

Data watchdog probes massive Deutsche Bank leak of 15M files

Nearly 300,000 children abroad receive German benefits, sparking political backlash

Editors Picks

l’accord capote sur fond de désaccord sur les énergies fossiles – POLITICO

November 22, 2026

Climate deal collapses amid fossil fuel rows – POLITICO

November 22, 2026

Emergency workers recover at least six body bags after Indonesian factory fire

November 22, 2026

Theresa May tells Burnham to move on – POLITICO

November 22, 2026

Subscribe to News

Get the latest Europe and world news and updates directly to your inbox.

Latest News

Mongolia faces snap presidential vote as outgoing leader calls for constitutional reform

November 22, 2026

Brussels, Charleroi airports to cancel most flights Monday amid Belgian strike – POLITICO

November 22, 2026

Video. Latest news bulletin | November 22nd, 2026 – Midday

November 22, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Europe. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.